
### [NCIT:C8319](http://purl.obolibrary.org/obo/NCIT_C8319)
**Label:** Stage II Lymphoma

**Subclasses:** [NCIT:C8937](http://purl.obolibrary.org/obo/NCIT_C8937) (Stage II B Lymphoblastic Lymphoma), [NCIT:C8518](http://purl.obolibrary.org/obo/NCIT_C8518) (Stage II Hodgkin Lymphoma), [NCIT:C8119](http://purl.obolibrary.org/obo/NCIT_C8119) (Stage II Grade 3 Follicular Lymphoma), [NCIT:C8117](http://purl.obolibrary.org/obo/NCIT_C8117) (Stage II Grade 2 Follicular Lymphoma), [NCIT:C8855](http://purl.obolibrary.org/obo/NCIT_C8855) (Stage II Diffuse Large B-Cell Lymphoma), [NCIT:C8877](http://purl.obolibrary.org/obo/NCIT_C8877) (Stage II Mediastinal (Thymic) Large B-Cell Cell Lymphoma), [NCIT:C8115](http://purl.obolibrary.org/obo/NCIT_C8115) (Stage II Small Lymphocytic Lymphoma), [NCIT:C8654](http://purl.obolibrary.org/obo/NCIT_C8654) (Stage II Lymphoplasmacytic Lymphoma), [NCIT:C8677](http://purl.obolibrary.org/obo/NCIT_C8677) (Stage II Angioimmunoblastic T-cell Lymphoma), [NCIT:C8116](http://purl.obolibrary.org/obo/NCIT_C8116) (Stage II Grade 1 Follicular Lymphoma), [NCIT:C5067](http://purl.obolibrary.org/obo/NCIT_C5067) (Stage II Lymphocyte-Depleted Classical Hodgkin Lymphoma), [NCIT:C9202](http://purl.obolibrary.org/obo/NCIT_C9202) (Stage II Mantle Cell Lymphoma), [NCIT:C94792](http://purl.obolibrary.org/obo/NCIT_C94792) (Stage II Childhood Non-Hodgkin Lymphoma), [NCIT:C8673](http://purl.obolibrary.org/obo/NCIT_C8673) (Stage II Nasal Type NK/T-Cell Lymphoma), [NCIT:C5086](http://purl.obolibrary.org/obo/NCIT_C5086) (Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue), [NCIT:C115030](http://purl.obolibrary.org/obo/NCIT_C115030) (Stage II Childhood Anaplastic Large Cell Lymphoma), [NCIT:C8055](http://purl.obolibrary.org/obo/NCIT_C8055) (Stage II Childhood Hodgkin Lymphoma), [NCIT:C5070](http://purl.obolibrary.org/obo/NCIT_C5070) (Stage II Nodular Lymphocyte Predominant Hodgkin Lymphoma), [NCIT:C68679](http://purl.obolibrary.org/obo/NCIT_C68679) (Stage II Marginal Zone Lymphoma), [NCIT:C8849](http://purl.obolibrary.org/obo/NCIT_C8849) (Stage II Burkitt Lymphoma), [NCIT:C7798](http://purl.obolibrary.org/obo/NCIT_C7798) (Stage II Mycosis Fungoides), [NCIT:C8843](http://purl.obolibrary.org/obo/NCIT_C8843) (Stage II B-Cell Non-Hodgkin Lymphoma), [NCIT:C8865](http://purl.obolibrary.org/obo/NCIT_C8865) (Stage II Nodal Marginal Zone Lymphoma), [NCIT:C8126](http://purl.obolibrary.org/obo/NCIT_C8126) (Stage II Adult Burkitt Lymphoma), [NCIT:C5077](http://purl.obolibrary.org/obo/NCIT_C5077) (Stage II Mixed Cellularity Classical Hodgkin Lymphoma), [NCIT:C8666](http://purl.obolibrary.org/obo/NCIT_C8666) (Stage II T-Cell Non-Hodgkin Lymphoma), [NCIT:C8124](http://purl.obolibrary.org/obo/NCIT_C8124) (Stage II Adult Immunoblastic Lymphoma), [NCIT:C8521](http://purl.obolibrary.org/obo/NCIT_C8521) (Stage II Non-Hodgkin Lymphoma), [NCIT:C8103](http://purl.obolibrary.org/obo/NCIT_C8103) (Stage II Adult Non-Hodgkin Lymphoma), [NCIT:C8125](http://purl.obolibrary.org/obo/NCIT_C8125) (Stage II Adult Lymphoblastic Lymphoma), [NCIT:C8683](http://purl.obolibrary.org/obo/NCIT_C8683) (Stage II Enteropathy-Associated T-Cell Lymphoma), [NCIT:C9057](http://purl.obolibrary.org/obo/NCIT_C9057) (Stage II Childhood Lymphoblastic Lymphoma), [NCIT:C8860](http://purl.obolibrary.org/obo/NCIT_C8860) (Stage II Follicular Lymphoma), [NCIT:C9033](http://purl.obolibrary.org/obo/NCIT_C9033) (Stage II Adult Hodgkin Lymphoma), [NCIT:C8660](http://purl.obolibrary.org/obo/NCIT_C8660) (Stage II Anaplastic Large Cell Lymphoma), [NCIT:C9186](http://purl.obolibrary.org/obo/NCIT_C9186) (Stage II Childhood Burkitt Lymphoma), [NCIT:C8691](http://purl.obolibrary.org/obo/NCIT_C8691) (Stage II Mature T- and NK-Cell Lymphoma), [NCIT:C5081](http://purl.obolibrary.org/obo/NCIT_C5081) (Stage II Nodular Sclerosis Classical Hodgkin Lymphoma), [NCIT:C68688](http://purl.obolibrary.org/obo/NCIT_C68688) (Stage II Indolent Adult Non-Hodgkin Lymphoma), [NCIT:C68686](http://purl.obolibrary.org/obo/NCIT_C68686) (Stage II Aggressive Adult Non-Hodgkin Lymphoma), [NCIT:C88153](http://purl.obolibrary.org/obo/NCIT_C88153) (Stage II Mycosis Fungoides and Sezary Syndrome), [NCIT:C8929](http://purl.obolibrary.org/obo/NCIT_C8929) (Stage II Centroblastic Lymphoma), 

**Class expressions from DL-Learner:**

- [NCIT:C28054](http://purl.obolibrary.org/obo/NCIT_C28054) (Stage II) 55.00%
- Thing 52.53%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 40.36%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 40.36%


